Table 4.
Population coverage analysis for the proposed epitopes against Chlamydia trachomatis
| Population | Coverage (%)a | Average hitb | PC90c |
|---|---|---|---|
| India | 100 | 6.38 | 1.31 |
| East Asia | 100 | 5.08 | 1.43 |
| Europe | 99.64 | 13.67 | 2.3 |
| Northeast Asia | 44.96 | 2.87 | 0.18 |
| South Asia | 100 | 6.41 | 1.31 |
| Southeast Asia | 100 | 3.99 | 1.33 |
| Southwest Asia | 58.14 | 6.8 | 0.24 |
| Central Africa | 49.95 | 5.0 | 0.2 |
| East Africa | 51.56 | 5.95 | 0.21 |
| North Africa | 57.84 | 7.04 | 0.24 |
| North America | 100 | 10.2 | 1.72 |
| Oceania | 56.01 | 3.93 | 0.23 |
| South Africa | 45.65 | 4.14 | 0.18 |
| South America | 100 | 6.09 | 1.35 |
| West Africa | 55.11 | 6.0 | 0.22 |
| West Indies | 66.66 | 7.87 | 0.3 |
aProjected population coverage
bAn average number of epitope hits/HLA combinations recognized by the population
cA minimum number of epitope hits/HLA combinations recognized by 90% of the population